Edwards lifesciences comments on ftc's action to block proposed acquisition of jenavalve

Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) announced today that the u.s. federal trade commission (ftc) moved to block the company's proposed acquisition of jenavalve technology. edwards disagrees with ftc's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (ar). the company further believes the acquisition of jenavalve will accelerate the availability, adoption and continued innovation of.
EW Ratings Summary
EW Quant Ranking